In clinical practice in 2020, we aimed to combine clinical presentation aspects, biological characteristics, and cytogenetics, but also TP53 mutations, in order to better define the risk of myeloma at initial assessment (Table 1). Here, TP53 is linked to plasma cell myeloma.